EXTRA-ABDOMINAL DESMOID TUMOR: LOCAL RECURRENCE AND TREATMENT OPTIONS
TEIXEIRA, LUIZ EDUARDO MOREIRA, ARANTES, EUGÊNIO COSTA, VILLELA, RAFAEL FREITAS, SOARES, CLAUDIO BELING GONÇALVES, COSTA, ROBERTO BITARÃES DE CARVALHO, ANDRADE, MARCO ANTÔNIO PERCOPE DE
Acta ortop. bras.
DATA DE PUBLICAÇÃO
ABSTRACT Objective: To evaluate the rate of local recurrence of extra-abdominal desmoid tumor and compare the outcomes of surgical treatment and conservative treatment. Methods: Twenty one patients (14 women and seven men), mean age 33.0±8.7 years old, with a diagnosis of desmoid tumor were evaluated. The mean follow-up period was 58.5±29.0 months. Fourteen cases involved the lower limbs, four cases involved the upper limbs, and three cases involved the trunk. The average tumor size was 12.7±7.5 cm. Of the 21 patients, 14 did not undergo previous treatment and seven patients relapsed before the initial evaluation. Surgical treatment was performed in 16 patients and conservative treatment was performed in five patients. Results: Recurrence occurred in seven patients (33%) and six of them relapsed within the first 18 months. No significant difference was observed between conservative and surgical treatment. However, a significant difference was observed among patients undergoing wide resection and who experienced improved local control. Conclusion: The recurrence rate of desmoid tumor was 33.3%. There was no difference in recurrence between conservative and surgical treatment. In surgical treatment, wide margins showed better results for recurrence control. Level of Evidence III. Retrospective Observational Study.
- A new extra-abdominal channel alternative to the mitrofanoff principle: experimental and preliminary clinical experience
- Inoperable Sacral Giant Cell Tumor: Therapeutic Options and Pain Control
- Giant desmoid tumor of the abdominal wall in a patient with Gardner Syndrome
- Abdominal aortic pseudoaneurysm associated with a metastatic germ cell tumor: a rare complication
- Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.